Abstract
The efficacy of regimens that include both zidovudine and nevirapine can be explained by the synergistic interactions between these drugs. N348I in HIV-1 reverse transcriptase confers decreased susceptibility to zidovudine and nevirapine. Here, we demonstrate that N348I reverses the synergistic inhibition of HIV-1 by zidovudine and nevirapine. Also, the efficiency of zidovudine-monophosphate excision in the presence of nevirapine is greater for N348I HIV-1 reverse transcriptase compared with the wild-type enzyme. These data help explain the frequent selection of N348I in regimens that contain zidovudine and nevirapine, and suggest that the selection of N348I should be monitored in resource-limited settings where these drugs are routinely used.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 153-157 |
| Number of pages | 5 |
| Journal | Journal of Acquired Immune Deficiency Syndromes |
| Volume | 61 |
| Issue number | 2 |
| DOIs | |
| State | Published - Oct 1 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Infectious Diseases
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver